E-DRUG: Non-commercial diseases (2)
-----------------------------------
Dear friends:
Just to put out an important issue as I can see. When we talk about
neglected diseases, it usually means that for non neglected diseases
-commercial diseases- we have enough, well oriented and succesfull research
and development of new drugs. So, Intellectual Property protection is
usefull and we only have to fix the especial situation of neglected
diseases. It is not exactly the true, if you look for the CPTECH existence
and day by day working, and if you think about a lot of examples of
manipulation of clinical trials (because of the commercial intention of the
research) manipulation of drugs indications, side effects etc. etc. In fact
a lot of people is thinking that IP protection is not useful for the society
as a whole and the Pharmaceutical industry is conducting an international
biased scheme for their financial interest.
Thanks
Francisco A. Rossi. B.
IPR and access to drugs project.
International Poverty Center.
UNDP - IPEA.
SBS. Ed BNDES, 15 andar. Sala 1513
70076-900 Brasilia D.F. Brazil.
(55 61) 315 - 5415
francisco_rossi@hotmail.com
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug